Literature DB >> 27121473

Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.

Wesley J Woollard1, Venu Pullabhatla2, Anna Lorenc2, Varsha M Patel1, Rosie M Butler1, Anthony Bayega1, Nelema Begum1, Farrah Bakr1, Kiran Dedhia1, Joshua Fisher1, Silvia Aguilar-Duran1, Charlotte Flanagan1, Aria A Ghasemi1, Ricarda M Hoffmann1, Nubia Castillo-Mosquera1, Elisabeth A Nuttall1, Arisa Paul1, Ceri A Roberts1, Emmanouil G Solomonidis1, Rebecca Tarrant1, Antoinette Yoxall1, Carl Z Beyers1, Silvia Ferreira1, Isabella Tosi1, Michael A Simpson3, Emanuele de Rinaldis2, Tracey J Mitchell1, Sean J Whittaker1.   

Abstract

Sézary syndrome (SS) is a leukemic variant of cutaneous T-cell lymphoma (CTCL) and represents an ideal model for study of T-cell transformation. We describe whole-exome and single-nucleotide polymorphism array-based copy number analyses of CD4(+) tumor cells from untreated patients at diagnosis and targeted resequencing of 101 SS cases. A total of 824 somatic nonsynonymous gene variants were identified including indels, stop-gain/loss, splice variants, and recurrent gene variants indicative of considerable molecular heterogeneity. Driver genes identified using MutSigCV include POT1, which has not been previously reported in CTCL; and TP53 and DNMT3A, which were also identified consistent with previous reports. Mutations in PLCG1 were detected in 11% of tumors including novel variants not previously described in SS. This study is also the first to show BRCA2 defects in a significant proportion (14%) of SS tumors. Aberrations in PRKCQ were found to occur in 20% of tumors highlighting selection for activation of T-cell receptor/NF-κB signaling. A complex but consistent pattern of copy number variants (CNVs) was detected and many CNVs involved genes identified as putative drivers. Frequent defects involving the POT1 and ATM genes responsible for telomere maintenance were detected and may contribute to genomic instability in SS. Genomic aberrations identified were enriched for genes implicated in cell survival and fate, specifically PDGFR, ERK, JAK STAT, MAPK, and TCR/NF-κB signaling; epigenetic regulation (DNMT3A, ASLX3, TET1-3); and homologous recombination (RAD51C, BRCA2, POLD1). This study now provides the basis for a detailed functional analysis of malignant transformation of mature T cells and improved patient stratification and treatment.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27121473     DOI: 10.1182/blood-2016-02-699843

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

Review 1.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

2.  Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.

Authors:  Kun Qu; Lisa C Zaba; Ansuman T Satpathy; Paul G Giresi; Rui Li; Yonghao Jin; Randall Armstrong; Chen Jin; Nathalie Schmitt; Ziba Rahbar; Hideki Ueno; William J Greenleaf; Youn H Kim; Howard Y Chang
Journal:  Cancer Cell       Date:  2017-06-15       Impact factor: 31.743

Review 3.  The biomarker landscape in mycosis fungoides and Sézary syndrome.

Authors:  Brittany Dulmage; Larisa Geskin; Joan Guitart; Oleg E Akilov
Journal:  Exp Dermatol       Date:  2017-02-02       Impact factor: 3.960

4.  Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma.

Authors:  Kim Wong; Carla Daniela Robles-Espinoza; David Rodriguez; Saskia S Rudat; Susana Puig; Miriam Potrony; Chi C Wong; James Hewinson; Paula Aguilera; Joan Anton Puig-Butille; Brigitte Bressac-de Paillerets; Hélène Zattara; Louise van der Weyden; Christopher D M Fletcher; Thomas Brenn; Mark J Arends; Víctor Quesada; Julia A Newton-Bishop; Carlos Lopez-Otin; D Timothy Bishop; Paul W Harms; Timothy M Johnson; Alison B Durham; David B Lombard; David J Adams
Journal:  JAMA Dermatol       Date:  2019-05-01       Impact factor: 10.282

5.  Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma.

Authors:  Melania H Fanok; Amy Sun; Laura K Fogli; Vijay Narendran; Miriam Eckstein; Kasthuri Kannan; Igor Dolgalev; Charalampos Lazaris; Adriana Heguy; Mary E Laird; Mark S Sundrud; Cynthia Liu; Jeff Kutok; Rodrigo S Lacruz; Jo-Ann Latkowski; Iannis Aifantis; Niels Ødum; Kenneth B Hymes; Swati Goel; Sergei B Koralov
Journal:  J Invest Dermatol       Date:  2017-11-08       Impact factor: 8.551

6.  Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).

Authors:  Joonhee Park; Jingyi Yang; Alexander T Wenzel; Akshaya Ramachandran; Wung J Lee; Jay C Daniels; Juhyun Kim; Estela Martinez-Escala; Nduka Amankulor; Barbara Pro; Joan Guitart; Marc L Mendillo; Jeffrey N Savas; Titus J Boggon; Jaehyuk Choi
Journal:  Blood       Date:  2017-07-10       Impact factor: 22.113

7.  DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.

Authors:  Tamara L Lotan; Harsimar B Kaur; Abdullah M Alharbi; Colin C Pritchard; Jonathan I Epstein
Journal:  Histopathology       Date:  2019-04-01       Impact factor: 5.087

8.  Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.

Authors:  Paola Rivera-Munoz; Anouchka P Laurent; Aurelie Siret; Cecile K Lopez; Cathy Ignacimouttou; Melanie G Cornejo; Olivia Bawa; Philippe Rameau; Olivier A Bernard; Philippe Dessen; Gary D Gilliland; Thomas Mercher; Sébastien Malinge
Journal:  Blood Adv       Date:  2018-07-10

Review 9.  Cutaneous T cell lymphoma.

Authors:  Reinhard Dummer; Maarten H Vermeer; Julia J Scarisbrick; Youn H Kim; Connor Stonesifer; Cornelis P Tensen; Larisa J Geskin; Pietro Quaglino; Egle Ramelyte
Journal:  Nat Rev Dis Primers       Date:  2021-08-26       Impact factor: 52.329

Review 10.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

Authors:  Alexander Neuwelt; Taha Al-Juhaishi; Eduardo Davila; Bradley Haverkos
Journal:  Blood Adv       Date:  2020-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.